Pertuzumab (Perjeta®) accepted for restricted use within NHS Scotland
Pertuzumab intravenous injection is approved for use in combination with trastuzumab and chemotherapy in the adjuvant treatment of HER2-positive early breast cancer at high risk of recurrence in patients with lymph node-positive disease.
Source:
Scottish Medicines Consortium